IO Biotech Inc Cash Flow Conversion Efficiency
IO Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, IO Biotech Inc (IOBT) has a cash flow conversion efficiency ratio of -20.283x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.48 Million) by net assets ($911.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of IO Biotech Inc (2019–2024)
Cash flow conversion efficiency of IO Biotech Inc from 2019 to 2024. This chart illustrates how IO Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of IO Biotech Inc for real-time trading data and today's change.
IO Biotech Inc Cash Flow Conversion Ratio Explained
IO Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
IO Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IO Biotech Inc ranked by their cash flow conversion efficiency. Also see IOBT stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ivory Properties Group Bhd
KLSE:5175
|
0.629x |
|
Sangrix Inc.
NASDAQ:SGRX
|
1.157x |
|
FRNT Financial Inc
V:FRNT
|
-0.111x |
|
Moolec Science SA Ordinary Shares
NASDAQ:MLEC
|
-0.059x |
|
Cora Gold Limited
LSE:CORA
|
-0.013x |
|
Panther Securities P L C
LSE:PNS
|
0.008x |
|
The Hydration Pharmaceuticals Company Ltd
AU:HPC
|
-0.606x |
|
Ristia Bintang Mahkotasejati
JK:RBMS
|
0.003x |
Annual Cash Flow Conversion Efficiency for IO Biotech Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of IO Biotech Inc from 2019 to 2024. Review how financially flexible is IO Biotech Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $47.02 Million | $-82.35 Million | -1.752x | -225.12% |
| 2023-12-31 | $133.16 Million | $-71.74 Million | -0.539x | -25.24% |
| 2022-12-31 | $138.85 Million | $-59.73 Million | -0.430x | -124.28% |
| 2021-12-31 | $211.92 Million | $-40.65 Million | -0.192x | +94.99% |
| 2020-12-31 | $2.60 Million | $-9.96 Million | -3.825x | -163.28% |
| 2019-12-31 | $-1.47 Million | $-8.89 Million | 6.044x | -- |
About IO Biotech Inc
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand … Read more